In the Asia-Pacific pharmaceutical industry, there were 88 M&A deals announced in Q3 2023, worth a total value of $4.4bn, according to GlobalData’s Deals Database. The $679.9m majority acquisition of Glenmark Life Sciences by Nirma was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in Asia-Pacific increased by 110% in Q3 2023 compared with the previous quarter’s total of $2.1bn and rose by 39% as compared to Q3 2022. Related deal volume decreased by 12% in Q3 2023 versus the previous quarter and was 7% higher than in Q3 2022.
The top-ranked financial advisors supporting these M&A deals in Asia-Pacific in Q3 2023 were Avendus Capital; Aizawa Securities; China Dragon Securities with 2, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Asia-Pacific Q3 2023 were Khaitan & Co; AZB & Partners; Freshfields Bruckhaus Deringer with 3, 2, 2 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.